During the past decade, Ophthalmic Consultants of Boston conducted 77 clinical trials. In the 10-year time frame, 77 clinical trials started and 36 clinical trials were completed, i.e. on average, 46.8% percent of trials that started reached the finish line to date. In the past 5 years, 31 clinical trials started and 27 clinical trials were completed. i.e. 87.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ophthalmic Consultants of Boston" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Pfizer" with 10 trials sponsored, "Jaeb Center for Health Research" with 8 trials sponsored, "Eyegate Pharmaceuticals, Inc." with 5 trials sponsored and "Apellis Pharmaceuticals, Inc." with 5 trials sponsored. Other sponsors include 82 different institutions and companies that sponsored additional 58 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ophthalmic Consultants of Boston" #1 collaborator was "National Eye Institute (NEI)" with 11 trials as a collaborator, "Genentech, Inc." with 8 trials as a collaborator, "Allergan" with 5 trials as a collaborator, "Novartis Pharmaceuticals" with 4 trials as a collaborator and "Regeneron Pharmaceuticals" with 4 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Ophthalmic Consultants of Boston" are "Diabetic Macular Edema" (21 trials), "Geographic Atrophy" (11 trials), "Macular Degeneration" (11 trials), "Diabetic Retinopathy" (6 trials) and "Macular Edema" (6 trials). Many other conditions were trialed in "Ophthalmic Consultants of Boston" in a lesser frequency.

Most popular intervention types in "Ophthalmic Consultants of Boston" are "Drug" (100 trials), "Other" (17 trials), "Biological" (11 trials), "Procedure" (9 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (12 trials), "Placebo" (6 trials), "Aflibercept" (5 trials), "Binimetinib" (4 trials) and "Faricimab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Ophthalmic Consultants of Boston" are 123 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Ophthalmic Consultants of Boston". undefined are not yet recruiting, 10 are recruiting, 19 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 77 completed trials in Ophthalmic Consultants of Boston, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Ophthalmic Consultants of Boston, 25 "Phase 1" clinical trials were conducted, 52 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".